1Montalescot G, Ankri A, Chadefaux-Vekemans B, et al. Plas- ma homocysteine and the extent of atherosclerosis in patients with conoary disease. Int J Cardio] 1997 ;60:295 -300.
2Hoogeveen EK, Konstense PJ, Valk GD,et al. Hyperhomocys- teinemia is not related to risk of distal somatic polyneuropathy : The Hoom Study. J Tntern Med 1999 ;264:561 -566.
3Cohen JA, Jeffer BW, et al. Increasing homocysteine levels and diabetic antonomic neropathy. Auton NEurosci 2001 ;87(2 -3) : 268 - 730.
4Ambrosch A, Dierkes J, Lobmann R, et al. Hyperhomocys- teinemia and endothelial dysfunction in IDDM. Diabet Med 2001 ; 18 : 185 - 192.
5Bruce SG, Young TK. Prevavence and risk factors for neurop- athy in a Canadian First Nation Community. Diabetes Care 2008 ;31 : 1837 - 1841.
6Ambrosch A, Dierkes J, Lobmann R,et al. Relation between homocystein- aemia and diabetes neuropathy in patients with Type 2 diabetic mellitus [J]. Diabet Med,2001 ;18(3) :185-92.
7de Luis DA, Fernandez N, Arranz ML, et al. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2 [ J]. J Diabetes Complications ,2005 ; 19 ( 1 ) :42-6.
8Baron H, Kidron M, Friedlander Y, et al. Plasma total homocysteine levels in subjects with hyperinsulinemia[ J ]. J Intern Med,2000 ;247 (2) : 287- 94.
9Fonseca VA, Fink LM, Kern PA. Insulin sensitivity and plasma homocysteine concentrations in non-diabetic obese and normal weight subjects [ J ]. Atherosclerosis, 2003 ; 167 ( 1 ) : 105-9.
10Maler JM, Seifert W, Huther G, et al. Homocysteine induces cell death of rat astrocytes in vitro[J]. Neurosci Lett J,2003 ;347(2) :85-8.
